ArticleScience translational medicine2019
Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 49 citations in OpenAlex.
- Sex-specific metabolic regulation by the Drosophila RNA-binding protein Nab2.bioRxiv : the preprint server for biology · 2026Article
- [Hereditary disorders of hemostasis in obstetrics 1/2-Anesthesiological aspects of primary hemostasis].Die Anaesthesiologie · 2026Review
- Riboregulation: a non-canonical tau function.Molecular neurodegeneration · 2026Review
- Loss of SMARCAD1 Mitigates Tauopathy.Aging cell · 2026Article
- Decoding the functions of nuclear speckles in neurodegeneration.Trends in neurosciences · 2026Review
- Article
- A kinetic ruler controls mRNA poly(A) tail length.Genes & development · 2025Article
- Polyserine-tau interactions modulate tau fibrillization.The Journal of biological chemistry · 2025Article
- Neuroprotective Potential of the Flavonoids Quercetin and Epicatechin in a C. elegans Tauopathy Model.Molecular nutrition & food research · 2025Article
- Tri-snRNP activity modulates tauopathy phenotypes.NAR molecular medicine · 2025Article
- Diverse influences on tau aggregation and implications for disease progression.Genes & development · 2025Review
- A Brief Review on Caenorhabditis elegans Role in Modelling Neurodegenerative Disease.Central nervous system agents in medicinal chemistry · 2025Review
- The RNA-binding protein Nab2 regulates levels of the RhoGEF Trio to govern axon and dendrite morphology.Molecular biology of the cell · 2024Article
- MSUT2 regulates tau spreading via adenosinergic signaling mediated ASAP1 pathway in neurons.Acta neuropathologica · 2024Article
- Tau-RNA complexes inhibit microtubule polymerization and drive disease-relevant conformation change.Brain : a journal of neurology · 2023Article
- Sut-6/NIPP1 modulates tau toxicity.Human molecular genetics · 2023Article
- Disrupting pathologic phase transitions in neurodegeneration.The Journal of clinical investigation · 2023Review
- Cytosolic condensates rich in polyserine define subcellular sites of tau aggregation.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- SPOP loss of function protects against tauopathy.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Molecular crowding and RNA synergize to promote phase separation, microtubule interaction, and seeding of Tau condensates.The EMBO journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 1 country.
Jeanna M WheelerGeriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA.ORCID 0000-0003-1999-2225
Pamela McMillanDepartment of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA 98195, USA.ORCID 0000-0003-1243-1951
Timothy J StrovasGeriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA.ORCID 0000-0002-0176-0293
Nicole F LiachkoGeriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA.ORCID 0000-0003-1250-3871
Alexandre Amlie-WolfDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-2073-1519
Rebecca L KowGeriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA.ORCID 0000-0001-7671-0832
Ronald L KleinDepartment of Pharmacology, Toxicology and Neuroscience, Louisiana State University Health Sciences Center, Shreveport, LA 71130, USA.
Patricia SzotDepartment of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA 98195, USA.ORCID 0000-0001-8939-8999
Linda RobinsonGeriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA.ORCID 0000-0003-0382-2619
Chris GuthrieGeriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA.ORCID 0000-0002-5408-1358
Aleen SaxtonGeriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA.ORCID 0000-0002-5055-5755
Nicholas M KanaanDepartment of Translational Sciences and Molecular Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI 49503, USA.ORCID 0000-0002-4362-2593
Murray RaskindDepartment of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA 98195, USA.ORCID 0000-0001-9763-2423
Elaine PeskindDepartment of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA 98195, USA.ORCID 0000-0002-3667-9129
John Q TrojanowskiDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-9239-8794
Virginia M Y LeeDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Li-San WangDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-3684-0031
C Dirk KeeneDepartment of Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA.ORCID 0000-0002-5291-1469
Thomas BirdGeriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA.
Gerard D SchellenbergDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0003-1115-2475
Brian KraemerGeriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA. kraemerb@uw.edu.ORCID 0000-0002-2252-7634
University of Puget Sound · USUniversity of Pennsylvania · USUniversity of Washington · USLouisiana State University Health Sciences Center Shreveport · USMichigan State University · US
Funding
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI JAYADEY, SUMAN · 1985 to 2019
$57.2MTransgenic Mouse Models of Tau PathologiesP01AG017586 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LEE, VIRGINIA M · 2000 to 2021
$37.3MUPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI XIE, SHARON XIANGWEN · 1991 to 2020
$35.1MDeveloping Neuroprotective Strategies for Tau and TDP-43 Proteinopathy in FTLDR01NS064131 · NINDS · SEATTLE INST FOR BIOMEDICAL/CLINICAL RES · PI KRAEMER, BRIAN C. · 2009 to 2022
$5.0MMSUT2 modulates pathological tau in AD and model organismsRF1AG055474 · NIA · SEATTLE INST FOR BIOMEDICAL/CLINICAL RES · PI KRAEMER, BRIAN C. · 2017 to 2017
$3.2MReversing tauopathy by inhibiting MSUT2 RNA-binding activityR56AG057642 · NIA · SEATTLE INST FOR BIOMEDICAL/CLINICAL RES · PI KRAEMER, BRIAN C. · 2019 to 2019
$573kMSUT2/SUT2 controls tau protein aggregation and neurotoxicity.I01BX000877 · VA · VA PUGET SOUND HEALTHCARE SYSTEM · PI KRAEMER, BRIAN C. · 2011 to 2014
–BLRD VA I01 BX000877BLRD VA I01 BX002619BLRD VA I01 BX004044NIA NIH HHS P01 AG017586NIA NIH HHS P50 AG005136NIA NIH HHS R56 AG057642NIA NIH HHS RF1 AG055474NINDS NIH HHS R01 NS064131
Abstract
Brain lesions composed of pathological tau help to drive neurodegeneration in Alzheimer's disease (AD) and related tauopathies. Here, we identified the mammalian suppressor of tauopathy 2 (
Indexed as
Alzheimer DiseaseAnimalsBrainCarrier ProteinsDisease Models, AnimalMaleMiceMice, TransgenicPoly(A)-Binding Protein IPoly(A)-Binding Proteinstau ProteinsCarrier ProteinsPABPN1 protein, mousePoly(A)-Binding Protein IPoly(A)-Binding Proteinstau Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.